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Strengths and limitations of this study
 ► Examines the important outcome of abortion rates 
over 1 year as an exploratory secondary analysis.
 ► Applicable only to women receiving levonogre-
strel emergency contraception (EC), followed by a 
desogestrel progestogen- only pill (POP).
 ► Not applicable to use of ulipristal acetate for EC, 
since hormonal methods of contraception, such as 
the desogestrel POP, may interact with efficacy of 
ulipristal acetate, if started within 5 days.
AbStrACt
Introduction Oral emergency contraception (EC) can 
prevent unintended pregnancy but it is important to start a 
regular method of contraception. Women in the UK usually 
access EC from a pharmacy but then need a subsequent 
appointment with a general practitioner or a sexual and 
reproductive health (SRH) service to access regular 
contraception. Unintended pregnancies can occur during 
this time.
Methods and analysis Bridge- It is a pragmatic cluster 
randomised cohort cross- over trial designed to determine 
whether pharmacist provision of a bridging supply of a 
progestogen- only pill (POP) plus rapid access to a local SRH 
clinic, results in increased uptake of effective contraception 
and prevents more unintended pregnancies than provision 
of EC alone. Bridge- It involves 31 pharmacies in three UK 
regions (London, Lothian and Tayside) aiming to recruit 
626–737 women. Pharmacies will give EC (levonorgestrel) 
according to normal practice and recruit women to both 
intervention and the control phases of the study. In the 
intervention phase, pharmacists will provide the POP 
(desogestrel) and offer rapid access to an SRH clinic. In the 
control phase, pharmacists will advise women to attend a 
contraceptive provider for contraception (standard care).
Women will be asked 4 months later about contraceptive 
use. Data linkage to abortion registries will provide 
abortion rates over 12 months. The sample size 
is calculated on the primary outcome of effective 
contraception use at 4 months (yes/no) with 90% power 
and a 5% level of significance. Abortion rates will be 
an exploratory secondary analysis. Process evaluation 
includes interviews with pharmacists, SRH clinicians and 
women. Cost- effectiveness analysis will use a healthcare 
system perspective and be expressed as incremental cost- 
effectiveness ratio.
Ethics and dissemination Ethical approval was received 
from South East Scotland REC June 2017. Results will 
be published in peer- reviewed journals and conference 
presentations.
trial registration number ISRCTN70616901.
IntroduCtIon
Unintended pregnancy is widely perceived as 
a major public health problem. Unintended 
pregnancy commonly ends in abortion and 
the UK has among the highest abortion rates 
in Europe.1 In 2017, almost 200 000 preg-
nancies ended in induced abortion.2 3 Unin-
tended pregnancy also ends in childbirth; 
around 10% of UK births are unintended 
and 25% mistimed.4 Unintended pregnancy 
is costly to the National Health Service (NHS) 
(estimated to cost over £1 billion annually)5 
and can be distressing for women. Unin-
tended pregnancies are more common in 
young women from deprived backgrounds, 
contributing to widening health inequal-
ities for both mother and baby, and their 
families.2 3 Unintended childbirth can have 
both socioeconomic consequences for 
women and their families and mental health 
consequences.6
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Oral emergency contraception (EC) prevents preg-
nancy in individual women following unprotected sex 
or contraceptive accidents. EC is only effective if taken 
before ovulation as it works by inhibiting or delaying 
ovulation.7 Since EC became available from pharmacies 
in the UK without the need for a prescription, there has 
been a change in the pattern of access such that women 
who seek EC now choose to obtain this from a pharmacy 
rather than a contraceptive provider such as a general 
practitioner (GP) or sexual and reproductive health 
(SRH) service.8 Although trials have shown that this facil-
itates access to EC and increases use, they have failed to 
show that this reduces unintended pregnancy rates within 
the population.9
There are two types of EC: the most widely used EC 
contains the progestogen levonorgestrel and should be 
taken within 72 hours of sex; the other EC contains the 
progesterone receptor modulator ulipristal acetate and 
should be taken within 120 hours of sex.10 Neither formu-
lation of EC prevents conceptions from subsequent acts 
of sex and the risk of pregnancy is increased up to three-
fold among women who have further unprotected sex in 
the same menstrual cycle after using EC than those who 
do not.10 An effective method of contraception should, 
therefore, be started as soon as possible.10 11 However, the 
only contraceptives that can be obtained from any phar-
macy without a prescription are condoms, which have 
high failure rates.12 This means that women usually need 
to make an appointment with a contraceptive provider 
(GP or SRH) and may experience delays in accessing 
regular contraception or lose the motivation to access a 
regular method altogether, which in turn may result in 
unintended pregnancies. In addition, although pharma-
cists in the UK are supposed to advise women on where 
to obtain ongoing contraception after EC, in one study 
fewer than half of pharmacists did so.13 It is possible 
that if pharmacists could supply a temporary (bridging) 
method of contraception to women along with EC, this 
would bridge the gap until women could get an appoint-
ment with a contraceptive provider for contraceptive 
advice and supplies. The progestogen- only pill (POP) is 
an effective method of contraception with few contra-
indications14 making it safer than the combined contra-
ceptive pill/oral contraceptives for pharmacy provision. 
However, studies have shown that starting hormonal 
contraception containing a progestogen within 5 days of 
ulipristal acetate may reduce the efficacy of EC and so 
only EC containing levonorgestrel is suitable for use in 
conjunction with a bridging method of hormonal contra-
ception in this way.15 16
Pilot
In a pilot study in Edinburgh of 168 women presenting 
for EC,17 11 pharmacies were randomised to one of 
three groups to provide EC (levonorgestrel) and either 
(1) standard advice on where to obtain ongoing contra-
ception or (2) 1 month of a POP or (3) the offer of 
rapid access to a local SRH service. Participants were 
contacted by telephone 6–8 weeks later to determine 
their current contraceptive use. Compared with standard 
care, the proportion of women using effective contra-
ception was significantly greater in both the POP (56% 
vs 16%, p=0.001) and the rapid access groups (52% vs 
16%, p=0.027). This suggests that a supply of 1 month 
of POP after EC or rapid access from a pharmacy to an 
SRH service might increase short- term uptake of effective 
contraception following EC.
We now propose a large randomised trial to determine 
whether a pharmacy- based intervention designed to 
facilitate the uptake of effective contraception after EC 
increases use of effective contraceptive methods including 
the most effective long- acting reversible contraceptive 
methods (LARC) such as the contraceptive implant and 
intrauterine contraception12 at 4 months when compared 
with standard care. We will examine contraceptive uptake 
at 4 months as most POP preparations are packaged as 
a 3- month supply and so by 4 months the pharmacy 
provided supply will have ended.
Aim
The aim is to develop a simple and affordable interven-
tion which facilitates the uptake of effective ongoing 
contraception among women obtaining EC from phar-
macies thereby reducing unintended pregnancy. The 
primary objective is to determine whether offering 
women attending a pharmacy for EC, a 3- month bridging 
supply of POP plus the offer of rapid access to a local 
SRH service results in increased uptake of effective 
contraception. The study POP (desogestrel) is commonly 
used in the UK. In contrast to other POP s, the desoges-
trel POP reliably inhibits ovulation and has similar effec-
tiveness to a combined hormonal contraceptive pill/
oral contraceptives (COCP), yet fewer contraindications 
than a COCP.14 15 This combined intervention (POP plus 
rapid access) offers both a highly safe temporary method 
of contraception and facilitates access to a specialist 
contraceptive service where all methods of contracep-
tion including the most effective LARC methods can be 
provided. If this intervention leads to increased uptake 
of effective contraception including LARC methods 
compared with standard care alone then we might expect 
that this would translate into fewer unintended pregnan-
cies for women.
MEthodS And AnAlySIS
Study design and setting
A pragmatic cluster randomised cohort cross- over trial 
with cost- effectiveness including process, outcome and 
economic evaluation involving 31 pharmacies in three 
UK regions (15 in London (South and Central), 12 
in Lothian (Edinburgh and region) and 4 in Tayside 
(Dundee and region).
Patient and public involvement
The members of the patient and public involvement 
(PPI) group at the SRH service in Edinburgh contributed 
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Figure 1 Bridge- it flow chart. POP, progestogen- only pill; 
SRH, sexual and reproductive health.
to the design of this study. The study protocol and docu-
mentation were reviewed and approved by the chair and 
members of the PPI group. The plain English summary 
was edited by a PPI member and improved as a result. 
There are three PPI members that participate and 
contribute to the Bridge- It Trial steering Committee 
meeting that provides oversight of the study. PPI group 
will be involved in the dissemination of the study results.
Intervention
The planned intervention is a composite intervention. 
Each woman in the intervention phase will receive 
3 months of POP (in a single package covering 3 months) 
and an invitation to attend a local participating SRH 
service to discuss and obtain effective contraception 
(including LARC methods). Three packets of POP, (75 
mcg desogestrel; UK) containing 28 tablets each will be 
provided at no cost to women as a bridging method of 
contraception, providing them with 3 months of contra-
ception during which time they can get an appointment 
with a contraceptive provider to obtain their preferred 
method of contraception. Locally approved patient 
group directions (ie, strict criteria to permit provision 
of specified medicines by non- prescribers) will permit 
participating pharmacists to dispense the POP to women 
recruited to the study. Prestudy training will be under-
taken with participating pharmacists including identi-
fying medical contraindications to POP, potential drug 
interactions medications and ‘missed pill’ guidance for 
POP. Pharmacists will advise women to start the POP the 
day following intake of EC10 and provide women with a 
patient information booklet on the POP from the family 
planning association ( www. fpa. org).
Pharmacists will encourage women to attend the partic-
ipating local SRH service to obtain the contraceptive 
method of their choice. Participants (intervention phase) 
will be given a study card to alert staff at SRH services 
that they are in the Bridge- It study and should be seen 
as a drop in for contraception that same day. This card 
will also provide written information about the loca-
tion and opening hours of the local participating SRH 
service. These SRH services are within a 5 mile radius of 
the participating pharmacies and provide all methods of 
contraception at no cost as is the norm in the NHS.
Standard care
A mystery shopper exercise13 will be undertaken in all 
31 participating pharmacies to characterise ‘standard 
care’ (usually verbal advice to visit a clinic for contra-
ception, with/without written and verbal information) 
in the control phase. The mystery shopper visits will be 
conducted when the pharmacy is not recruiting and just 
before the control phase starts. The mystery shoppers and 
the scenario used will be chosen by the PPI group. A simple 
scenario relating to request for EC will be used. Immedi-
ately after leaving the pharmacy, the mystery shopper will 
complete a standard data collection proforma, recording 
any information given by the pharmacist about use of 
contraception after taking EC, including provision of 
written information.
Participants
We will recruit a total of 626–737 women presenting 
for EC. The final number will be determined based on 
the observed ratio of the between- period within- cluster 
correlation (BPC) and the within- period within- cluster 
correlation (WPC)—with the larger sample size (near 
the 737 upper limit) required for values of BPC close 
to zero, and the smaller sample size (near the 626 lower 
limits) required for values of BPC close to WPC.18 Each 
pharmacy will be expected to recruit an average of 12–13 
women to the intervention arm and 12–13 women to 
standard care. This allows for a 25% lost to follow- up at 
4 months (missing data on primary outcome).
randomisation
Each pharmacy will be randomised to either the inter-
vention phase for approximately 20 weeks followed by 
standard care phase for 20 weeks or vice versa with a 
washout period of 2 weeks between the two phases. The 
order in which pharmacy allocation to each arm is under-
taken (intervention or control first) will be randomised 
(figure 1).The order of delivery of intervention or control 
for each pharmacy was randomised for this cluster cross- 
over design from a randomisation file prepared by the 
study statistician in the Data Centre at the Centre for 
Healthcare Randomised Trials (CHaRT), University of 
Aberdeen, using SAS V.6.4 for Windows. The method 
used for generating the random unpredictable mix of 
permuted blocks was a computer software algorithm that 
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Table 1 Study outcomes
Data source
Main outcome
  Use of effective 
contraceptive method 
(hormonal or intrauterine) in 
intervention versus control 
at 4 months
Self- reported (telephone or 
self completed survey) at 4 
months
Secondary outcomes
  Numbers undergoing an 
abortion within 12 months 
intervention versus control
National abortion registries
  Economic evaluation Incremental cost- 
effectiveness ratio for 
pregnancies prevented
box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Intake of EC (levonorgestrel).
 ► Capacity to give informed consent to participate in the trial which 
includes adherence to trial requirements.
 ► Age 16 years or over.
 ► Willing to give contact details and be contacted at 4 months by 
phone or text or email or post.
 ► Willing to give identifying data sufficient to allow data linkage with 
NHS registries.
Exclusion criteria
 ► Contraindications to the progestogen- only pill (POP).
 ► On medication that interacts adversely with POP.
 ► Already using a hormonal method of contraception.
 ► Require interpreting services.
 ► If pharmacist has concerns about non- consensual sex.
EC, emergency contraception; NHS, National Health Service.
randomly allocated blocks of size 2, 4 and 6; blocking was 
used to ensure balanced group sizes.
This is a cluster cohort cross- over design so it is the phar-
macy that is the unit of randomisation and the 'cross- over' 
means that we are just randomising the order that each 
pharmacy gives the intervention in. The ‘cohort’ label 
means that we expect different women to be recruited 
within each site in the two periods (intervention and 
control phases).
recruitment
The pharmacist will assess medical eligibility of women 
presenting for EC for the study, provide EC according to 
normal practice and invite eligible women to participate. 
A detailed patient information sheet will be provided 
to all women and informed consent will be obtained by 
participating community pharmacists. The EC used in 
this study is levonorgestrel and will be given in the clin-
ically indicated dose for the woman’s weight (1.5 mg or 
3 mg levonorgestrel).10
Inclusion and exclusion criteria are shown in box 1. 
Women who give written consent will be recruited in the 
study. We recognise the importance of participant reten-
tion and will offer a voucher of £10 at recruitment.19
outcomes
A full list of study outcome measures is included in 
table 1. Outcomes at 4 months will primarily be collected 
via telephone interviews or via web- based questionnaires. 
However, participants will also have the option to provide 
the same information by a postal questionnaire. The 
primary outcome is use of effective contraception at 
4 months (intervention vs standard care).
Secondary outcomes are proportion of participants 
having an abortion within 12 months of EC use using 
record linkage from participants to national registries 
and cost- effectiveness.
Process evaluation measures
A process evaluation will be conducted as part of the 
study to assess potential issues concerning intervention 
implementation, the causal mechanisms of impact and 
the contextual factors that could affect these. The process 
evaluation will comprise of quantitative and qualitative 
data measures, as detailed in box 2.
data collection
Quantitative data
Participant flow: Participant flow through the study will 
be assessed and reported following the Consolidated 
Standards of Reporting Trials flow chart.
Baseline
Participant demographics and reproductive history is 
collected at recruitment by a self- administered paper 
questionnaire given to them by the pharmacist. Demo-
graphic data will also be reported for the process evalua-
tion, protocol adherence checklists and for recruitment 
screening forms (see box 2).
Contraceptive use at 4 months
This will be based on self- reported data from women at 
a telephone follow- up interview with a research nurse at 
4 months after obtaining EC. If participants prefer, the 
questions can be self- completed by a web- based question-
naire or paper questionnaire sent by the post. Women will 
be asked what method of contraception they are using (if 
any), if they attended a GP or SRH service for this, if they 
used the POP (intervention phase only) and their preg-
nancy status. If pregnancy has occurred since EC then 
the validated London Measure of Unintended Pregnancy 
tool will be administered to measure intended- ness of the 
index pregnancy20 (table 1).
Abortion rates at 12 months
Information Services Division (Scotland) and Depart-
ment of Health (England) will provide the number of 
abortions occurring during the 12- month follow- up 
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box 2 Process evaluation methods and data
theory
Theory of change model
Study team
Pharmacy recruitment forms (study team members involved in recruit-
ment will routinely record decision- making contributing to pharmacy 
selection, including: number of contacts made; responses from potential 
pharmacists; rationales for inclusion/exclusion and reasons for refusal).
Pharmacists
Participant observation of training and review of training and interven-
tion materials.
Recruitment monitoring forms (n=100% of pharmacists) and protocol 
adherence checklists (n=100% of pharmacists).
Follow- up semistructured telephone interviews with pharmacists 
(n=27; one with each pharmacy involved).
Sexual and reproductive health (Srh) providers
Semistructured telephone interviews with SRH providers (n=12; with 
service manager, mix staff at 2x services in London; 1x service in 
Edinburgh; 1x service in Dundee).
Participants
Telephone questionnaire administered by research nurse at 4 months 
postintervention (n=100% participants).
Semistructured telephone interviews at 4 months postintervention 
(n=60; 22 in London, 30 in Edinburgh and 8eight in Dundee).
Context
Audit of local contraceptive services within 10 miles of study sites in 
London, Edinburgh and Dundee.
Monitoring of contemporaneous events, such as relevant high coverage 
media stories using Google Alerts.
period in each arm by conducting linkage of the identi-
fiers (collected at baseline) from study participants.
Validation
We will check with data from local SRH services to deter-
mine the numbers of participants from intervention 
and control phases who attend the local participating 
SRH service, and which method of contraception they 
received.
Qualitative data
Semistructured, qualitative telephone interviews of a 
purposive sample of up to 60 women who received the 
intervention (approximately 22 in London, 30 in Edin-
burgh and 8 in Dundee) will be undertaken. Partici-
pants who consent to these telephone interviews will be 
contacted by the Process Evaluation Research Assistant. 
Interviews will explore experience of intervention accept-
ability in more depth and assess experiences of bridging 
from EC to regular contraception, and reasons for doing 
so or not (Box 2). Interviews will be conducted soon after 
the 4- month follow- up.
Interviews with 27 pharmacists and 12 SRH service 
providers will explore their perceptions of barriers 
and facilitators to implementation and more broadly, 
their views on the intervention, the trial and the target 
population. Interviews will be conducted by the process 
evaluation research assistant soon after the intervention 
phase has completed.
For the process evaluation, data collection also includes: 
review of training and materials, observation of training, 
mapping of local contraceptive services within 10 miles of 
study sites and monitoring of contemporaneous events, 
such as relevant high coverage media stories using Google 
Alerts (box 2).
Sample size calculation
The study is a pragmatic cluster randomised cohort cross- 
over trial. Ideally the control and intervention phases 
should be of roughly equal duration and size, and the 
sample size is calculated assuming an equal cluster size in 
both control and intervention periods, and equal across 
sites (the expected site/period average). In practice, 
there is variability in EC demand across sites and over 
time, for example, demand is affected by peak holiday 
periods (recruitment decreases) and student term times 
(recruitment increases); and the ability of a pharmacy to 
translate that variable demand into study recruits depends 
on many factors, including changes to circumstances at 
individual pharmacies or loss of/change of pharmacists 
at multipharmacist stores.
Informed by our pilot study, we have assumed that effec-
tive contraception use in the control would be 30% and 
we were likely to achieve a 50% relative improvement to 
45%. This means the sample size is in the range 626–737, 
assuming 25% of women do not provide 4- month contra-
ceptive use data, and an average cluster size of 12–13 in 
each period, and around 25 pharmacies taking part, with 
90% power and a 5% level of significance. The uncertainty 
in the required sample size rests on the assumed BPC and 
its relationship to the other component of variability, the 
WPC.18 The WPC is the usual correlation (known as the 
intraclass correlation in a standard parallel groups non- 
cross- over cluster setting) of two individuals’ outcomes 
within a cluster (in the same period). The BPC on the 
other hand is the correlation between two individuals’ 
outcomes in the same cluster between the two periods. 
If the BPC is zero, there is no advantage in a cross- over 
design over the standard parallel groups cluster design; if 
the BPC equals the WPC then the crossover is as efficient 
as an individually randomised design. We will finalise the 
sample size depending on the observed ratio of the BPC to 
WPC, and the observed rate of attrition, but still assuming 
the same control rate and treatment effect, once we have 
4- month data on at least 500 participants.
Quantitative analyses
There will be a single analysis at study end (there is no 
opportunity for any interim analyses given the cross- 
over design) although an independent data monitoring 
committee will monitor study progress and any safety issues. 
This will follow the intention- to- treat principle and will use 
a hierarchical model appropriate for the specific outcome. 
For the primary outcome, this will be a mixed- effects 
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logistic regression, using the hierarchical model approach 
as recommended by Turner et al for a cluster cross- over 
design.21 We will prespecify any individual level (or cluster 
level) covariates that we intend to adjust for, and the 
comprehensive statistical analysis plan will specify the sensi-
tivity type analyses that will explore how robust the find-
ings are to any missing data at the cluster level (probably 
unlikely) and the individual level (expected to be substan-
tial for the patient reported outcomes at 4 months). As well 
as the usual assumption of missing at random, we will try to 
explore possible mechanisms for non- ignorable (informa-
tive missingness) at the individual level, which may well be 
operating in this context. Subgroup analyses will explore 
the possible effect modification by LARC (most effective 
contraceptive methods) versus non- LARC vs no use of 
contraception.
Qualitative and mixed-methods process evaluation analyses
All process data will be analysed independently of the 
outcome data and, importantly, documented before the 
outcomes are known. Qualitative analysis of in- depth inter-
views will be recorded and transcribed verbatim. Transcrip-
tion and analysis (proceeding case by case) will start with 
the first interview and be ongoing during the course of data 
collection, allowing for emergent themes to be identified 
and explored in future interviews. The transcripts will be 
read repeatedly and coded for analysis. Data management 
will be assisted by the software, QSR NVivo V.10. Analysis 
will be undertaken using ‘Framework Analysis’ a method 
of proven validity and reliability where data are coded, 
indexed and charted systematically, then organised using a 
matrix or framework.22 Constant comparison will be carried 
out to ensure that the analysis represents all perspectives 
and negative (‘deviant’) cases.
The multisource process evaluation will be synthesised to 
address the three key process evaluation questions: (1) what 
was delivered, (2) how it was delivered and (3) what role 
context may have had in shaping the delivery/outcomes
Economic evaluation
An economic evaluation will be undertaken comparing the 
intervention and control arms in a cost- effectiveness anal-
ysis. A trial- based analysis will be followed by the construc-
tion of a decision model to extrapolate future costs and 
benefits beyond the completion of the trial. The overall 
perspective used will be that of the health system. Costs will 
include the pharmacist training to provide POP, direct and 
indirect costs of health service use, and the provision and 
dispensing of POP. We will compare the costs to the NHS 
in the intervention and control arms. To account for differ-
ences in the numbers of women in the two arms, we will 
compare the cost per woman in each arm. In the control 
arm, the costs are (1) cost of EC, (2) cost of pharmacist 
provision of EC, (3) cost of abortions. In the intervention 
arm, the costs are in addition to these (4) the cost of the 
POP, (5) cost of pharmacist training to provide POP and 
(6) cost of pharmacist provision of POP. The costs (1) and 
(2) are the same in both groups and so the extra cost of 
the intervention will be the sum of (4), (5) and (6). The 
cost per women who has an abortion is the same in both 
groups except that we hypothesise that the abortion rate 
will be lower in the intervention group. We can then state 
the outcome as conventional incremental cost- effectiveness 
ratio that is, for every £100 spent on the intervention results 
in x fewer abortions for a savings of £Y. If Y is greater than 
100 then the intervention is cost- effective. We will examine 
the sensitivity of the outcomes to variations in the costs of 
4, 5 and 6.
data management and clinical trial unit support
Data will be collected on a paper case report form and will be 
entered directly into the trial database. Data will be entered 
into a trial database by pharmacists, research nurses or staff 
at the trial coordinating centre. The data management and 
statistical support (including responsibility of data and final 
dataset) for the study is provided by the UKCRC registered 
Clinical Trial Unit (CTU) the CHaRT at the University 
of Aberdeen while the trial management is provided by 
another UKCRC registered CTU, the Edinburgh Clinical 
Trials Unit (ECTU) at Edinburgh University.
Ethics and dissemination
The Bridge- It trial involves procedures and medications, 
which are well established in current NHS clinical prac-
tice and use. Adverse events may occur during or after the 
use of EC or POP and are well documented in the POP 
patient information leaflet. Serious adverse events will be 
recorded at the 4- month follow- up interview and reported 
to the study sponsor. The study will be conducted in 
accordance with the principles of Good Clinical Practice.
Annual progress reports and a final report at the 
conclusion of the trial will be submitted to REC within 
the timelines defined in the regulations. Protocol modifi-
cations are communicated by the ECTU to study sites via 
email and electronic newsletters.
The Bridge- It study website will include trial materials, 
trial progress and summaries of key findings. In addition, 
public engagement and dissemination will also be under-
taken via our PPI group.
The results of the study will be published in the 
academic journals and all participants will be offered a 
lay summary of the main findings of the study. The find-
ings will also be presented at national and international 
conferences and disseminated via social media.
trial status
As at 7 February 2019, the study had recruited 503 partic-
ipants across 29 sites. Recruitment to the first period 
completed on 13 January 2019, with 391 participants 
recruited at 29 sites. Recruitment is scheduled to be 
completed by June 2019, with analyses of the 4- month 
primary outcome expected to be available by October 2019.
dISCuSSIon
Unintended pregnancy is widely perceived as a major 
public health problem. The proposed intervention in the 
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Open access
Bridge- It study provides both temporary contraception 
(the POP) and facilitates access to effective contraception 
at a local SRH clinic. The cluster design was felt necessary 
for logistical reasons and confirmed in the qualitative work 
of our pilot study17 23 that an individually randomised trial 
would simply not recruit, as it was not feasible for phar-
macists within a busy pharmacy to take additional time to 
randomise each individual. The cross- over nature of the 
cluster design was chosen for efficiency, and by having a 
different set of women recruited at a pharmacy in the two 
different periods we avoided contamination by the partici-
pant. The purpose of the washoutout period was to mini-
mise intervention effect carrying over from one period to 
another, as part of any contamination effect mediated by 
the pharmacist. With the cluster cross- over design, each 
cluster will act as its own control and fewer pharmacies are 
required than with a parallel cluster design.
If our proposed intervention works, then this could 
prevent more unintended pregnancies for more women. 
If the intervention is cost- effective then it could have cost 
savings for the NHS.
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